Law360, New York (June 3, 2013, 10:22 PM EDT) -- A federal judge said Monday that Bristol-Myers Squibb Co.’s practice of subsidizing patients’ drug copays didn't constitute illegal bribery, dismissing a putative class action brought by insurers that complain the payments push patients to choose brand-name drugs over cheaper generics.
U.S. District Judge J. Paul Oetken said the payments do not run afoul of laws against commercial bribery because consumers have no duty to keep their insurance companies’ costs down.
The decision is an important one in a legal battle that has pitted drug companies and their...
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.